Trial Profile

A Phase 1b/2a study of MTX240

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTX 240 (Primary)
Indications Gastrointestinal stromal tumours
Focus Therapeutic Use

Most Recent Events

14 Apr 2026 New trial record
02 Apr 2026 According to a Biodexa Pharmaceuticals media release, the company plans to file an IND and initiate a Phase 1b/2a study towards the end of the year. The company has has partnered with Syngene International for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com